Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONL1204 for Geographic Atrophy Associated With Age-related Macular Degeneration
2024-513174-22-00Phase 2Authorised
- Sponsor
- ONL Therapeutics
- Start
- Aug 2025
- Modality
- Small Molecules, Peptides
- Countries
- 13
01
Overview
Phase 2, randomised, double-blind trial of xelafaslatide in age-related macular degeneration (AMD) (3 arms), sponsored by ONL Therapeutics. Primary endpoint: GA lesion area assessment. Planned start Aug 2025; status: authorised.
02
Drugs
xelafaslatide
03
Conditions
age-related macular degeneration (AMD)
Beyond the preview
Go deeper on 2024-513174-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513174-22-00.